Lloyd J. Old: Difference between revisions
/External Links/ add Cancer Research Institute homepage to |
added middle initial to Lloyd J. Old, added cancer control quote |
||
| Line 1: | Line 1: | ||
'''Dr. Lloyd Old''' holds the William E. Snee Chair of Cancer Immunology at [[Memorial Sloan-Kettering Cancer Center]] (MSKCC), is a Professor of Immunology at [[Weill Cornell Graduate School of Medical Sciences]], is Director of the Scientific Advisory Council of the [http://www.cancerresearch.org Cancer Research Institute], and is Chairman of the [[Ludwig Institute for Cancer Research]] (LICR). He is also a Trustee of the LICR Charitable Trust, a Trustee of the Virginia & D.K. Ludwig Fund for Cancer Research, which created the Ludwig Cancer network in 2006, and Director of the LICR New York Branch. Since 2001, Dr. Old has also served as director of the Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative. Dr. Old’s previous appointments include LICR Scientific Director (1988 to 2005), Member of the Emeritus LICR Scientific Committee (1971-86), LICR Chief Executive Officer (1995-2004), and Associate Director of Research at MSKCC (1973-83). |
'''Dr. Lloyd J. Old''' holds the William E. Snee Chair of Cancer Immunology at [[Memorial Sloan-Kettering Cancer Center]] (MSKCC), is a Professor of Immunology at [[Weill Cornell Graduate School of Medical Sciences]], is Director of the Scientific Advisory Council of the [http://www.cancerresearch.org Cancer Research Institute], and is Chairman of the [[Ludwig Institute for Cancer Research]] (LICR). He is also a Trustee of the LICR Charitable Trust, a Trustee of the Virginia & D.K. Ludwig Fund for Cancer Research, which created the Ludwig Cancer network in 2006, and Director of the LICR New York Branch. Since 2001, Dr. Old has also served as director of the Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative. Dr. Old’s previous appointments include LICR Scientific Director (1988 to 2005), Member of the Emeritus LICR Scientific Committee (1971-86), LICR Chief Executive Officer (1995-2004), and Associate Director of Research at MSKCC (1973-83). |
||
Dr. Old’s contributions to research over the past three decades have established many of the principles and priorities of modern tumor immunology. In earlier work, he and his colleagues introduced [[Bacillus Calmette-Guérin|BCG]] to tumor immunotherapy ; discovered the first link between the major histocompatibility complex and disease (leukemia); found the unexpected association between [[Epstein-Barr virus]] and [[nasopharyngeal carcinoma]]; discovered [[Tumor necrosis factors|tumor necrosis factor]]; defined the concept of cell-surface differentiation antigens with the discovery of TL , Lyt (CD8) and a range of other mouse antigenic systems; co-discovered [[P53]] with two other groups; and identified the tumor immunogenicity of [[heat shock proteins]]. Dr. Old is the author or co-author of more than 600 research publications. |
Dr. Old’s contributions to research over the past three decades have established many of the principles and priorities of modern tumor immunology. In earlier work, he and his colleagues introduced [[Bacillus Calmette-Guérin|BCG]] to tumor immunotherapy ; discovered the first link between the major histocompatibility complex and disease (leukemia); found the unexpected association between [[Epstein-Barr virus]] and [[nasopharyngeal carcinoma]]; discovered [[Tumor necrosis factors|tumor necrosis factor]]; defined the concept of cell-surface differentiation antigens with the discovery of TL , Lyt (CD8) and a range of other mouse antigenic systems; co-discovered [[P53]] with two other groups; and identified the tumor immunogenicity of [[heat shock proteins]]. Dr. Old is the author or co-author of more than 600 research publications. |
||
| Line 18: | Line 18: | ||
"Human benefit is our unyielding yardstick." - on measuring success in cancer research |
"Human benefit is our unyielding yardstick." - on measuring success in cancer research |
||
"Control of cancer will be a critical element in the eventual mastery of cancer." - on the seeking as a desireable clinical endpoint long-term tumor dormancy through the artifical restoration immune equilibrium via vaccination and other cancer immunotherapies. |
|||
==External links== |
==External links== |
||
| Line 26: | Line 28: | ||
* [http://www.sciam.com/article.cfm?id=cancer-clues-from-embryos/ Old interviewed in ''American Scientist'' May 2009] |
* [http://www.sciam.com/article.cfm?id=cancer-clues-from-embryos/ Old interviewed in ''American Scientist'' May 2009] |
||
{{DEFAULTSORT:Old, Lloyd}} |
{{DEFAULTSORT:Old, Lloyd J.}} |
||
[[Category:Year of birth missing (living people)]] |
[[Category:Year of birth missing (living people)]] |
||
[[Category:Living people]] |
[[Category:Living people]] |
||
Revision as of 13:40, 10 June 2009
Dr. Lloyd J. Old holds the William E. Snee Chair of Cancer Immunology at Memorial Sloan-Kettering Cancer Center (MSKCC), is a Professor of Immunology at Weill Cornell Graduate School of Medical Sciences, is Director of the Scientific Advisory Council of the Cancer Research Institute, and is Chairman of the Ludwig Institute for Cancer Research (LICR). He is also a Trustee of the LICR Charitable Trust, a Trustee of the Virginia & D.K. Ludwig Fund for Cancer Research, which created the Ludwig Cancer network in 2006, and Director of the LICR New York Branch. Since 2001, Dr. Old has also served as director of the Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative. Dr. Old’s previous appointments include LICR Scientific Director (1988 to 2005), Member of the Emeritus LICR Scientific Committee (1971-86), LICR Chief Executive Officer (1995-2004), and Associate Director of Research at MSKCC (1973-83).
Dr. Old’s contributions to research over the past three decades have established many of the principles and priorities of modern tumor immunology. In earlier work, he and his colleagues introduced BCG to tumor immunotherapy ; discovered the first link between the major histocompatibility complex and disease (leukemia); found the unexpected association between Epstein-Barr virus and nasopharyngeal carcinoma; discovered tumor necrosis factor; defined the concept of cell-surface differentiation antigens with the discovery of TL , Lyt (CD8) and a range of other mouse antigenic systems; co-discovered P53 with two other groups; and identified the tumor immunogenicity of heat shock proteins. Dr. Old is the author or co-author of more than 600 research publications.
As part of a distinguished service career Dr. Old has served as a member of scientific advisory boards and committees including the Public Health Research Institute of the City of New York, the National Cancer Institute, and the American Association for Cancer Research. Dr. Old is also a member of the American Association for Cancer Research, New York Academy of Sciences, Reticuloendothelial Society, Society of Experimental Biology and Medicine, American Association for the Advancement of Science, American Association of Immunologists, National Academy of Sciences, the Academy of Cancer Immunology, and the American Academy of Arts and Sciences. He has also received honorary doctor of medicine degrees from Karolinska Institute, the University of Lausanne, and the University College London. He is a graduate of the University of California, Berkeley with a B.A. in biology and holds a medical degree from the University of California School of Medicine, San Francisco.
Awards
- 1975: Cancer Research Institute William B. Coley Award
- 1985: New York Academy of Medicine Medal
- 2004: President's Medal, Johns Hopkins University
- 2004: Dean's Award, Stanford University School of Medicine
- 2007: Charles Rodolphe Brupbacher Prize for Cancer Research
Quotes
"When you're looking for diamonds, you don't throw out the rubies." - on why unanticipated research findings should be investigated.
"You won't know how to vaccinate until you know how to immunize. And you won't know how to immunize until you know how to monitor." - on the use of immunological monitoring as part of cancer vaccine development.
"Human benefit is our unyielding yardstick." - on measuring success in cancer research
"Control of cancer will be a critical element in the eventual mastery of cancer." - on the seeking as a desireable clinical endpoint long-term tumor dormancy through the artifical restoration immune equilibrium via vaccination and other cancer immunotherapies.